Drug updated on 5/2/2024
Dosage Form | Injection (intravenous; 300 mg, 400 mg) |
Drug Class | Monoclonal antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Summary
- Elotuzumab (Empliciti) is used in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- It is also combined with pomalidomide and dexamethasone for treating adult patients with multiple myeloma who have undergone at least two previous treatments including lenalidomide and a proteasome inhibitor.
- Two systematic reviews/meta-analyses were reviewed, providing insights into the effectiveness of elotuzumab (Empliciti) when compared to other drug regimens in treating multiple myeloma.
- In a network meta-analysis involving 123 randomized controlled trials, triplet therapy containing monoclonal antibodies like elotuzumab was found superior for lenalidomide-refractory multiple myeloma; specifically, elotuzumab/pomalidomide/dexamethasone had higher efficacy than just using dexamethasone alone.
- Another Bayesian network meta-analysis indicated that daratumumab/lenalidomide/dexamethasone showed clear advantages over other IMiD-containing regimens such as carfilzomib/lenaldiomde/dexmethsane or ixazamib/lenaldiomde/dexmethsane; however, it did not specify how Empliciti performed relative to these combinations.
- The results from both analyses suggest that while Empliciti can be effective in certain combinations against refractory MM cases, more research may be needed to ascertain its optimal use among different patient subgroups and against various competing drug regimens.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Empliciti (elotuzumab) Prescribing Information. | 2022 | Bristol-Myers Squibb Company., Princeton, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Safety and efficacy of elotuzumab combination therapy for patients with multiple myeloma: a systematic review and meta-analysis. | 2022 | Expert Review of Anticancer Therapy |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. | 2022 | European Review for Medical and Pharmacological Sciences |
A systematic review and network meta-analysis of randomized data on efficacy of novel therapy combinations in patients with lenalidomide-refractory multiple myeloma. | 2021 | Clinical Lymphoma, Myeloma & Leukemia |
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. | 2020 | Expert Review of Hematology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. | 2023 | Journal of the NCCN |
Clinical practice guideline multiple myeloma. | 2022 | Myeloma Australia |
Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. | 2021 | Annals of Oncology |
Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. | 2019 | Journal of Clinical Oncology |